Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans

Using a crossover design, we will compare the effects of a placebo to an angiotensin II
receptor antagonist on the urinary sodium excretion response in obese normotensive subjects
and untreated hypertensive African-Americans subjects. We expect that the urinary sodium
excretion response to angiotensin II receptor antagonist therapy will be less in the
overweight/obese hypertensive subjects compared to the overweight/obese normotensive
subjects. This study will also employ a double blind placebo controlled cross-over drug
study. All subjects that qualify to participate in this study will fall in the
overweight/obese category with a BMI rate of 25 kg/m2 or higher. Half of the subjects will be
normotensive and half drug naïve hypertensive. The normotensive subjects will be identified
as described above for Studies 1 and 2. The only difference is that they will need to have a
BMI greater than or equal to 25 kg/m2. The hypertensive subjects will be identified by Dr.
White or his team in the hypertension clinic. These patients will be restricted to those not
currently on anti-hypertensive therapy.

This study will involve a screening visit, two first dose visits and two testing weeks over
an approximate 5 week period (this includes a one week "washout" period).

Each testing week will have a 3 day salt-controlled diet prior to testing and an approximate
3-hour testing period on Day 4. The 3-hour testing period will include 10 minutes of a
baseline rest, 45 minutes of mild stress (competitive video game), and 45 minutes of a
recovery rest. A total of 4 blood and 4 urine samples will be collected during the 3-hour
period. Each blood draw will consist of about 7 teaspoons for a total of 28 teaspoons per
week. If female, a pregnancy test will be performed at the beginning of each testing visit
(screening, first dose-1, test day-1, first dose -2 and test day-2) to confirm that they are
not pregnant. The week before testing, the subject will come to the Georgia Prevention
Institute or Children's Research Unit for the First Dose Visit and meet with one of the study
physicians who will give me instructions on how to take Avapro. This appointment will last
about 2 ½ hours. They will take their first dose of Avapro or the placebo and will be
monitored for the next 2 hours. If female subject, they will provide a urine sample for a
pregnancy test to make sure they are not pregnant before they are given the first dose of the
study medication. During this time, their blood pressure will be taken every 15 minutes.

During the screening and testing, each subject will be asked to take the MoCA (the Montreal
Cognitive Assessment) test in order to measure cognitive thinking after stress. It is a brief
30-question test which takes around 10 minutes to complete. It measures different types of
cognitive abilities, including orientation (the approximate position of something/someone),
short-term memory (remember information for a short period of time), executive function
(planning and problem solving), language abilities (assign appropriate names to appropriate
items), and visuospatial ability (determine distance from one object to another). Each
question is awarded a particular number of points depending on the accuracy of the answers
given. We will be looking to see if the total number of points earned changes in response
before and after stress. During the screening visit, they subject will take the MoCA test
which will take approximately 10 minutes. Someone from the research team will instruct the
subject as to what to do for each question and they will answer each one to the best of their
ability.

On testing day, a nurse/phlebotomist will insert a small needle attached to a plastic tube
called a catheter into a vein in the hand or arm. This procedure will allow the
nurse/phlebotomist to collect the 4 blood samples over the 3-hour testing period. The needle
stick may cause some temporary pain and may result in a black and blue mark. A device that
automatically takes blood pressure will then be put on the opposite arm. The subject will
also be given water to sip on during the duration of testing. Before testing begins, the
subject be instructed to take their last dose of medication. During the first 10 minute
baseline rest period, they will relax in a reclining chair. They can listen to music, read a
book or magazine or watch movies to pass the time. Blood pressure will be taken before and
after this 10 minute rest period. Once the baseline rest period is over, a blood and urine
sample will be collected.

During the stress period, the subject will play a video game against another subject for 45
minutes. Blood pressure will continue to be measured every 10 minutes. They will also
continue to sip on water during this time. At the end of the game, another blood and urine
sample will be collected.

The subject will then be asked to complete the MoCA test a second time. It will be the same
questions that was asked during the screening visit. A research team member will instruct the
subject again as to how to answer each question and they will answer them to the best of
their ability.

The last 45 minute recovery period of relaxation will be the same as the first (reading,
listening to music or watching movies). Blood pressure will continue to be taken every 10
minutes. Once the 45 minutes has ended the last blood and urine sample will be collected and
the testing day will have been completed. They will repeat this whole process a second time.

During test day one or test day two, each subject will have a Dual Energy X-ray
Absorptiometer (DEXA) scan and a Peripheral Quantitative Computer Tomography (pQCT) scan
performed on them The DEXA is to assess bone mineral density (BMD), body fat percentage and
lean tissue. The pQCT will assess bone strength at the radius and tibia. For The DEXA, the
subject will remove any items that may contain metal - including jewelry, belts, shoes and
piercings. A gown will be provided if needed. The subject will lie on a table for
approximately 6 minutes, while the table rotates and a mechanical arm moves above the subject
body measuring for the BMI. For the pQCT, the subject will be seated and position their
forearm into the pQCT device and remain still for 3-5 minutes. They will then place their
lower leg into the same device for another 3-5 minutes to be scanned. If the subject is
female, a pregnancy test will be performed before any testing begins for each testing visit
in order to confirm the subject is not pregnant.

Bone and Body Composition Measurements

Dual-energy X-ray absorptiometry will be performed at baseline and posttest to assess total
body composition. The body composition variables of interest will be fat-free soft tissue
mass and fat mass.

Peripheral quantitative computed tomography will be performed at baseline visit only to
assess bone strength at the radius and tibia. During the scan, the participant must place
their forearm or lower leg into the pQCT unit and remain still for three to five minutes
(actual scan duration for each).

For the forearm scan, the participant is seated in a chair at the side of the pQCT unit. The
participant sits as close as possible to the unit. The shoulder should be close to the front
side of the gantry. The armrest of the machine is adjusted to the measured forearm length.
The elbow is fixed at the corner of the armrest with the Velcro strap and the distal forearm
is fixed with the clamp. The angle between upper arm and forearm should not exceed 90°. The
hand lies on the hand rest. The fixation of the arm should prevent movement artifacts but
must not hurt. The participant is asked to search for a convenient and natural position to
avoid movement or discomfort during the scanning period of 3-5 minutes.

For the lower leg scan, the participant is seated on a chair in front of the pQCT unit. When
the machine is at the start position, the participant's lower leg is moved through the gantry
and the foot is rested on the foot holder. With the foot holder positioned all the way to the
front of the pQCT unit, the lower leg is centered and fixed into the concentric acrylic
cylinder (diameter 18 cm), which is located at the gantry opening. The foot is now fixed with
the Velcro strap to the foot holder. Before the scan, the participant is asked to find a
convenient and natural position to reduce movement artifacts during the 3-5 minute scan.

Radial and tibial measurements will be taken at the 4% and 20% sites for bone outcomes,
proximal to the articular surface of the distal end of the tibia and radius. The 4% and 20%
sites represent areas high in trabecular and cortical bone, respectively. Each scan will be
acquired with a 0.4 mm voxel size and a slice thickness of 2.4 mm. The anatomic reference
line (for determination of the distal end of the radius or tibia) will be identified by
acquisition of a 30 mm planar scout view of the joint line and automatically set by the
software at 4% or 20% sites. Image processing and calculation of the bone measures will be
determined using the Stratec software (version 6.02 d).

At the trabecular sites of the radius and tibia, total volumetric bone mineral density (vBMD,
mg/cm3) and total cross-sectional area (CSA, mm2) will be measured to calculate bone strength
index (BSI; mg2/mm4, Equation 1), an estimate of bone's ability to withstand compressional
strains. At the cortical bone sites of the radius and tibia, cortical vBMD (mg/cm3), cortical
CSA (mm2), and cortical thickness (mm) will be measured to calculate the strength-strain
index (SSI, mm3), which reflects torsional bone strength. The SSI is calculated as the
integrated product of the section modulus and the density of cortical bone (Equation 2).
Section modulus is calculated as (a x d2)/dmax, where a is the CSA of a voxel, d is the
distance of the voxel from the center of gravity, and dmax is the maximum distance of one
voxel to the center of gravity. The ratio of cortical vBMD and normal physiological density
(ND = 1200 mg/cm3) provides an estimate of the modulus of elasticity.

Inclusion Criteria:

- African-American

- not pregnant

- have a BMI (Body Mass Index) rate of 25 kg/m2 or higher

- currently not taking any medications that may affect my blood pressure

Exclusion Criteria:

- not African-American

- pregnant

- a BMI (Body Mass Index) rate less than 25 kg/m2

- taking medications that will affect my blood pressure